All
Research
Education
Business
Solutions
EN
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Türkçe
JA - 日本語
PL - Polski
RU - Русский
HE - עִברִית
AR - العربية
Sign In
Lynne Jesaitis has not added Biography.
If you are Lynne Jesaitis and would like to personalize this page please email our Author Liaison for assistance.
Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome.
Clinical pharmacokinetics Dec, 2014 | Pubmed ID: 25234648
Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.
Clinical therapeutics May, 2015 | Pubmed ID: 25487082
Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome.
Journal of immunological methods 01, 2017 | Pubmed ID: 27789297
Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.
Clinical therapeutics Jan, 2017 | Pubmed ID: 27955919
Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment.
Molecular genetics and metabolism Apr, 2018 | Pubmed ID: 29526614
BioMarin Pharmaceutical Inc
Ruby Cheung1,
Gregory W. deHart1,
Lynne Jesaitis1,
Stephen J. Zoog1,
Andrew C. Melton1
1, BioMarin Pharmaceutical Inc
Privacy
Terms of Use
Policies
Contact Us
Recommend to library
JoVE NEWSLETTERS
JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archive
JoVE Core
JoVE Science Education
JoVE Lab Manual
JoVE Quiz
JoVE Playlist
Authors
Librarians
Access
ABOUT JoVE
JoVE Sitemap
Copyright © 2025 MyJoVE Corporation. All rights reserved
We use cookies to enhance your experience on our website.
By continuing to use our website or clicking “Continue”, you are agreeing to accept our cookies.
Learn More